Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
Journal of Clinical Medicine
|
September 13, 2025
A Novel Scoring System for the Administration of an IgM- and IgA-Enriched Intravenous Immunoglobulin Preparation: The SORRISO Score
Mattia Bixio, Lucio Torelli, Alice Scamperle, et al.
Anticancer Research
|
October 3, 2018
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma
Matteo Santoni, Francesco Piva, Ugo De Giorgi, et al.
Expert Review of Cardiovascular Therapy
|
December 13, 2019
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies
Matteo Santoni, Alessandro Conti, Francesco Massari, et al.
Journal of Thoracic Disease
|
January 15, 2021
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions
Rossana Berardi, Gaia Goteri, Silvia Pagliaretta, et al.
Oncotarget
|
August 9, 2015
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
Rossana Berardi, Alessandro Brunelli, Silvia Pagliaretta, et al.
Targeted Oncology
|
January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
Matteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Annals of Surgical Oncology
|
December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors
Matteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Plos One
|
April 18, 2015
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?
Francesco Pantano, Matteo Santoni, Giuseppe Procopio, et al.
Oncotarget
|
March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
Daniele Santini, Matteo Santoni, Alessandro Conti, et al.
The Journal of Urology
|
July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma
Matteo Santoni, Alessandro Conti, Camillo Porta, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
Journal of Clinical Medicine
|
September 13, 2025
A Novel Scoring System for the Administration of an IgM- and IgA-Enriched Intravenous Immunoglobulin Preparation: The SORRISO Score
Mattia Bixio, Lucio Torelli, Alice Scamperle, et al.
Anticancer Research
|
October 3, 2018
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma
Matteo Santoni, Francesco Piva, Ugo De Giorgi, et al.
Expert Review of Cardiovascular Therapy
|
December 13, 2019
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies
Matteo Santoni, Alessandro Conti, Francesco Massari, et al.
Journal of Thoracic Disease
|
January 15, 2021
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions
Rossana Berardi, Gaia Goteri, Silvia Pagliaretta, et al.
Oncotarget
|
August 9, 2015
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
Rossana Berardi, Alessandro Brunelli, Silvia Pagliaretta, et al.
Targeted Oncology
|
January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
Matteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Annals of Surgical Oncology
|
December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors
Matteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Plos One
|
April 18, 2015
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?
Francesco Pantano, Matteo Santoni, Giuseppe Procopio, et al.
Oncotarget
|
March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
Daniele Santini, Matteo Santoni, Alessandro Conti, et al.
The Journal of Urology
|
July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma
Matteo Santoni, Alessandro Conti, Camillo Porta, et al.
Page
of 8